Brief: Leqembi® Q3 Revenue Totaled Jpy 10 Billion
30/10/2024 13:33
Oct 30 (Reuters) - BioArctic AB BIOAb.ST :
* LEQEMBI® REVENUE TOTALED JPY 10 BILLION IN THE THIRD
QUARTER
2024
* BIOARCTIC'S PARTNER EISAI TODAY PUBLISHED PRELIM GLOBAL
REVENUE
FOR LEQEMBI DURING Q3 2024, IN CONJUNCTION WITH THEIR PARTNER
BIOGEN'S QUARTERLY REPORT
Source text: ID:nWkr7TwdQp
Further company coverage: BIOAb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln